PDCD1 and neoplasm: Hence, in this study, we investigated tumor growth speed before starting nivolumab in patients treated with anti-PD-1 monotherapy as an alternative to immunohistochemistry, and aimed to analyze whether MGR could be concise and feasible method to predict clinical outcome of mRCC patients treated with ICIs.